404 related articles for article (PubMed ID: 31391211)
1. Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.
Dunn KE; Huhn AS; Bergeria CL; Gipson CD; Weerts EM
J Pharmacol Exp Ther; 2019 Nov; 371(2):422-452. PubMed ID: 31391211
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
3. Medications Development for Treatment of Opioid Use Disorder.
Townsend EA; Negus SS; Banks ML
Cold Spring Harb Perspect Med; 2021 Jan; 11(1):. PubMed ID: 31932466
[TBL] [Abstract][Full Text] [Related]
4. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management.
Pergolizzi JV; Raffa RB; Rosenblatt MH
J Clin Pharm Ther; 2020 Oct; 45(5):892-903. PubMed ID: 31986228
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive memantine for opioid use disorder treatment: A systematic review.
Elias AM; Pepin MJ; Brown JN
J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol.
Kudrich C; Hurd YL; Salsitz E; Wang AL
Cannabis Cannabinoid Res; 2022 Oct; 7(5):569-581. PubMed ID: 34678050
[No Abstract] [Full Text] [Related]
7. Addiction: the clinical interface.
Nutt D; Lingford-Hughes A
Br J Pharmacol; 2008 May; 154(2):397-405. PubMed ID: 18414399
[TBL] [Abstract][Full Text] [Related]
8. Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance.
Luba R; Jones J; Choi CJ; Comer S
Addiction; 2023 Apr; 118(4):719-726. PubMed ID: 36444486
[TBL] [Abstract][Full Text] [Related]
9. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
10. Combating opiate dependence: a comparison among the available pharmacological options.
Gonzalez G; Oliveto A; Kosten TR
Expert Opin Pharmacother; 2004 Apr; 5(4):713-25. PubMed ID: 15102558
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
12. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.
Cisewski DH; Santos C; Koyfman A; Long B
Am J Emerg Med; 2019 Jan; 37(1):143-150. PubMed ID: 30355476
[TBL] [Abstract][Full Text] [Related]
13. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
[TBL] [Abstract][Full Text] [Related]
14. Establishing a research agenda for the study and assessment of opioid withdrawal.
Dunn KE; Strain EC
Lancet Psychiatry; 2024 Jul; 11(7):566-572. PubMed ID: 38521089
[TBL] [Abstract][Full Text] [Related]
15. Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets.
Rehni AK; Jaggi AS; Singh N
CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):112-25. PubMed ID: 23244430
[TBL] [Abstract][Full Text] [Related]
16. Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development.
Negus SS; Banks ML
Pharmacol Biochem Behav; 2018 Jan; 164():32-39. PubMed ID: 28442370
[TBL] [Abstract][Full Text] [Related]
17. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
18. Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control.
Chu LF; Rico T; Cornell E; Obasi H; Encisco EM; Vertelney H; Gamble JG; Crawford CW; Sun J; Clemenson A; Erlendson MJ; Okada R; Carroll I; Clark JD
Drug Alcohol Depend; 2018 Feb; 183():176-183. PubMed ID: 29278818
[TBL] [Abstract][Full Text] [Related]
19. Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.
Bisaga A; Mannelli P; Sullivan MA; Vosburg SK; Compton P; Woody GE; Kosten TR
Am J Addict; 2018 Apr; 27(3):177-187. PubMed ID: 29596725
[TBL] [Abstract][Full Text] [Related]
20. Opioid antagonists with minimal sedation for opioid withdrawal.
Gowing L; Ali R; White JM
Cochrane Database Syst Rev; 2009 Oct; (4):CD002021. PubMed ID: 19821290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
